Roux-en-Y gastric bypass versus best medical treatment for type 2 diabetes mellitus in adults with body mass index between 27 and 32 kg/m
Class I obesity
Continuous glucose monitoring
Glucagon-like peptide 1 receptor agonist
Roux-en-Y gastric bypass
Sodium-glucose cotransporter 2 inhibitor
Type 2 diabetes mellitus
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
02
09
2021
revised:
24
04
2022
accepted:
27
04
2022
pubmed:
6
5
2022
medline:
22
6
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
To evaluate the effects of Roux-en-Y gastric bypass (RYGB) versus best medical treatment in Asians with type 2 diabetes mellitus (T2DM) and class I obesity. In this 5-year single-centre, open-label randomized controlled trial, participants were randomized to RYGB or medical treatment including newer classes of diabetes medications (ClinicalTrials.gov:NCT02041234). The primary endpoint was diabetes remission defined as HbA1c ≤ 6% (≤42 mmol/mol) and discontinuation of glucose-lowering medication at 12 months post-intervention and beyond. Glycaemia and weight changes were assessed. Continuous glucose monitoring was performed. Of 28 subjects randomized, 26 were analyzed in the final cohort (14 medical, 12 RYGB; age:44 ± 10 years, 34.6% males, BMI:29.4 ± 1.6 kg/m Over 5 years, RYGB outperforms best medical treatment in glycemia and weight improvements for Asians with T2DM and class I obesity.
Identifiants
pubmed: 35513159
pii: S0168-8227(22)00714-8
doi: 10.1016/j.diabres.2022.109900
pii:
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Banques de données
ClinicalTrials.gov
['NCT02041234']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
109900Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.